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Abstract
Background: Whether newer antihypertensive drugs, such as calcium channel blockers,
angiotensin converting enzyme inhibitors and α blockers are more effective than thiazides and β
blockers in preventing coronary disease, has been debated for years.  
Discussion: Recently several trials addressing this issue have been finalised, and they provide a
convincing answer: the newer drugs are no better than the older ones. In the largest trial to date
(ALLHAT), thiazide-type diuretic was found to offer advantages over newer drugs. The medical
community should now be capable of reaching consensus, and recommend thiazides as the first line
therapy for the treatment of hypertension. Prescribing physicians, cardiologists, drug companies
and health authorities are all partly responsible for the years of irrational prescribing that we have
witnessed.
Summary: All stakeholders should now contribute in order to achieve what is clearly in the
public's interest: implementing the use of thiazides in clinical practice.
Background
The debate over first choice drug for the treatment of
hypertension has been intense for years. Opinions have
mainly differed with regard to the role of calcium channel
blockers, angiotensin converting enzyme inhibitors, α
blockers, and more recently the angiotensin II receptor
antagonists. These drugs have been shown to effectively
lower blood pressure, but until recently their effectiveness
with regards to matters of importance, namely health out-
comes such as reduction in myocardial infarctions and
strokes, had not been proven. In contrast, thiazide diuret-
ics and β blockers have been tested in numerous clinical
trials, and have been shown to reduce the risk of cardio-
vascular disease in people with hypertension.
The effectiveness of hypertension treatment
Hypertension is associated with an increased risk of stroke
and coronary heart disease. A review of clinical trials from
the 1960s, 70s and 80s showed that the use of thiazides
and β blockers had a convincing effect on stroke preven-
tion – the added risk associated with elevated blood pres-
sure was markedly reduced with such treatment [1].
However, the drugs were not as effective at preventing cor-
onary heart disease – although the risk went down, per-
sons on treatment still had a significantly higher risk than
persons without hypertension [1]. One hypothesis was
that the lack of full effect was caused by detrimental met-
abolic effects of thiazides and β blockers, e.g. changes in
blood lipids or glucose tolerance [2].
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New antihypertensive drugs were introduced in the
1980s: calcium channel blockers, angiotensin converting
enzyme inhibitors and α blockers. They were shown to
reduce blood pressure effectively and they seemed to be
superior to thiazides and β blockers with regards to meta-
bolic effects [2]. Consequently the medical community
became rather enthusiastic with the prospect of getting
newer and better tools in the prevention of coronary heart
disease. The problem was that no clinical trials had been
conducted showing that the new drugs did what they were
meant to do: prevent people from falling ill or dying. The
resulting controversy concerned the interpretation of evi-
dence available at the time. Some physicians argued that
the likelihood of the newer being better was strong
enough to warrant these drugs to be considered as first
line in the treatment of hypertension [3]. Others warned
about jumping on new interventions before they had
been properly tested, meaning clinical trials with clini-
cally relevant outcome measures such as incidence of
stroke, heart attacks and deaths [4].
Clinical trials comparing new and old drugs
It took several years before clinical trials were initiated
investigating the effectiveness of the new antihyperten-
sives with regards to disease prevention. Clinical trials of
new drugs are usually supported by grants from the phar-
maceutical industry, but since the drugs had achieved
huge sales without such trials, there was little incentive for
the companies to push the issue. For instance, the calcium
channel blocker amlodipine became the number one sell-
ing antihypertensive few years after introduction to the
market – with little or no evidence of its ability to improve
people's health. Finally, in the mid-90s and onwards, sev-
eral clinical trials comparing the effectiveness of thiazides
and β blockers with the newer drug classes began [5-11].
Most of the trials were sponsored by the pharmaceutical
industry, and had the clear objective of proving that newer
is better. The debate over first choice agents continued
while the trials were ongoing, but all agreed that the
results would provide the answer: are the newer drug
classes more effective than thiazides and β blockers at pre-
venting coronary heart disease?
Discussion
Now, many of the trials have been finalised and the results
are available [5-11]. Disappointingly, in all but one of
these trials [11], neither calcium channel blockers, angi-
otensin converting enzyme inhibitors nor α blockers per-
formed better than thiazides or β blockers. In contrast, the
results of the most extensive study to date (ALLHAT) indi-
cate that chlorthalidone (thiazide-type diuretic) may in
fact be superior to the newer drug-classes [6,7]. This study
in particular, gives strong weight to the recommendation
of choosing thiazides as first choice drugs for hyperten-
sion. All the study results have recently been combined in
two meta-analyses, demonstrating that thiazides reduce
cardiovascular risk at least as effectively as other antihy-
pertensive drugs [12,13]. In addition, the use of thiazides
as first choice therapy will mean substantial cost savings
due to their favourable price [14]. Thus, finally, after more
than a decade of controversy, the medical community
should be capable of reaching a clear consensus: thiazides
are, again, the primary agents for the treatment of hyper-
tension [15-17]. However, it should be noted that more
than one drug is often needed to control hypertension.
In retrospect
Despite intense debate, e.g. in medical journals, calcium
channel blockers, angiotensin converting enzyme inhibi-
tors and α blockers rapidly dominated clinical practice, as
evidenced by their market shares in most western coun-
tries all through the 1990s. This was, assumingly, a result
of effective marketing from drug companies [18,19].
Luckily, choosing calcium channel blockers or angi-
otensin converting enzyme inhibitors did probably not
cause much harm to patients with hypertension who
could have taken thiazides or β blockers instead. How-
ever, the use of α blockers may have caused some harm to
patients as evidenced by the higher incidence of conges-
tive heart failure among patients randomised to doxa-
zosin (α blocker) verus chlorthalidone (thiazide-type
diruetic) [7]. In addition, physicians who opted for cal-
cium channel blockers, angiotensin converting enzyme
inhibitors or α blockers as first choice drugs for hyperten-
sion have put unnecessary strain on health expenses.
What can we learn?
Obviously, prescribing physicians need to rethink their
practice, but there are a few additional issues that deserve
some reflection. Firstly, a critical attitude towards relying
on surrogate endpoints when evaluating medical inter-
ventions needs to be re-emphasised [20]. A surrogate end-
point is "a laboratory measurement or a physical sign
used as a substitute for a clinically meaningful end point
that measures directly how a patient feels, functions or
survives"[20]. For example, the claim that the α blockers'
positive impact on blood lipids would reduce the risk of
heart disease was not confirmed, rather the contrary [7].
Effectiveness in terms of blood pressure lowering is
another popular surrogate endpoint (see note at end of
article), which is of questionable value if the objective is
to reduce cardiovascular risk [21]. Secondly, the role of
opinion leaders cannot be ignored. During the 1990s car-
diologists typically acted as speakers at events hosted by
industry where they would preach the superiority of cal-
cium channel blockers, angiotensin converting enzyme
inhibitors or α blockers over thiazides and β blockers
(author's personal experience). Despite the need to be
humble when operating in the light of retrospect, it seemsPage 2 of 4
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between industry and opinion leaders. Conflicts of inter-
est may be an issue [22], and the methods employed by
specialty societies in developing clinical practice guide-
lines should be examined [23]. Thirdly, this example illus-
trates how the agenda of the pharmaceutical industry may
be contrary to public interests. Profits made from older
drugs are minute compared to what may be earned on
newer, patent-protected drugs. Finally, health authorities
cannot be freed from liability. Both in terms of taking care
of the public's health and public money, governmental
agencies are obliged to address irrational prescribing pat-
terns.
Summary
Now, the challenge is to implement the use of thiazides in
clinical practice. This is not in the interest of drug compa-
nies, and they may wish to antagonise initiatives promot-
ing increased use of thiazides (or β blockers) [24].
Opinion leaders, such as cardiologists, should take the
lead and promote thiazides as drugs of choice. Continued
support for drugs on the basis of surrogate endpoints is
unethical now that hard clinical evidence is on the table.
Health authorities may find it difficult to identify inter-
ventions that will influence physicians' prescribing [25].
Effective interventions such as educational outreach visits
are costly, and massive programs such as those run by
drug companies, even more so. The available evidence
suggests that multifaceted interventions may be effective
[26]. Identifying barriers to change and addressing these
through tailor made, multifaceted interventions may
prove to be an effective strategy [27].
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Note
A figure was meant to be included in this article to illus-
trate the pharmaceutical industry's use of surrogate end-
points for marketing purposes. A graphic taken from
http://www.norvasc.com, which also included an intrigu-
ing link to the results of the ALLHAT study (ALLHAT-
results do not support the use of the drug in the advertise-
ment), could not be reprinted since Pfizer Inc. failed to
respond to a request to use their artwork. The author has
sent monthly requests per e-mail since 13. August 2003,
and has also been in contact with the company per tele-
phone. Despite this, at the time of publication there was
still no sign of a decision from Pfizer.
The views expressed in this article are not necessarily in
accordance with the views of the Norwegian Directorate
for Health and Social Affairs.
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